Compare MOVE & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOVE | VIVS |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 8.1M |
| IPO Year | 2021 | N/A |
| Metric | MOVE | VIVS |
|---|---|---|
| Price | $8.57 | $1.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 139.2K | 41.6K |
| Earning Date | 03-19-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | $140,000.00 |
| Revenue This Year | $1,460.71 | $42.38 |
| Revenue Next Year | $96.77 | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 35.92 |
| 52 Week Low | $4.67 | $1.41 |
| 52 Week High | $69.68 | $21.96 |
| Indicator | MOVE | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 36.62 |
| Support Level | $7.22 | $2.11 |
| Resistance Level | $9.72 | $2.51 |
| Average True Range (ATR) | 1.08 | 0.15 |
| MACD | -0.29 | 0.00 |
| Stochastic Oscillator | 29.48 | 10.97 |
Movano Inc is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. its initial commercial product in development is the Evie Ring, a wearable designed specifically for women. The Evie Ring combines health and wellness metrics to give a full picture of one's health, which includes resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.